Sex-based survival differences in IDH-wildtype glioblastoma: Results from a retrospective cohort study
| Autor: | Tom Boterberg, J.P. Kalala, D. Van Roost, C. Van den Broecke, Harry Pinson, Giorgio Hallaert |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology medicine.medical_specialty Neurology Physiology (medical) Internal medicine medicine Humans DNA Modification Methylases Survival analysis Retrospective Studies Temozolomide Brain Neoplasms Proportional hazards model business.industry Retrospective cohort study General Medicine DNA Methylation Prognosis Isocitrate Dehydrogenase DNA Repair Enzymes Isocitrate dehydrogenase Cohort Female Surgery Neurology (clinical) Glioblastoma business Chemoradiotherapy medicine.drug |
| Zdroj: | Journal of Clinical Neuroscience. 91:209-213 |
| ISSN: | 0967-5868 |
| Popis: | A female survival benefit has been described for glioblastoma patients. Recent studies report that the effect of 06-methylguanine-DNA-methyltransferase gene promoter (MGMTp) methylation is only present in female patients. We retrospectively studied sex-based survival, including MGMTp-methylation, in a cohort of 159 uniformly treated isocitrate dehydrogenase wildtype (IDHwt) patients. All patients were treated with temozolomide-based chemoradiotherapy after surgery. Kaplan-Meier survival curves and Cox regression models were used to evaluate overall survival. The study included 59 female (37.1%) and 100 male patients (62.9%). There were no statistically significant differences between sexes concerning demographic, surgical or radiological characteristics. Female patients harbored MGMTp-methylated tumors in 45.8% of cases and males in 33% (P = 0.129). Median overall survival was 13.4 months for men and women alike. After adjustment of survival for age, Karnofsky Performance Score, extent of resection and MGMTp-methylation, sex did not have a significant survival impact. However, MGMTp-methylation proved to be an independent beneficial prognosticator for both sexes, contradicting earlier reports. Several sex-based molecular subtypes of glioblastoma with different response to current treatment may exist explaining conflicting survival results in different patient cohorts. Further research on sex-based differences in IDHwt glioblastoma patients is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect